GC Genome Corporation (KOSDAQ:340450)

Market Cap	233.43B +34.7%
Revenue (ttm)	32.64B +13.7%
Net Income	5.42B +41,017.6%
EPS	229.79 +33,695.5%
Shares Out	23.65M
PE Ratio	42.95
Forward PE	43.10
Dividend	n/a
Ex-Dividend Date	n/a

Volume	525,157
Open	10,010.00
Previous Close	10,140.00
Day's Range	9,560.00 - 10,130.00
52-Week Range	4,100.00 - 10,380.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About GC Genome

GC Genome Corporation operates as a clinical genome analysis company in South Korea. It offers hereditary cancer, tissue and liquid biopsy genetic, blood cancer, and homologous recombination deficiency tests under the Green Plan names; Guardant360, a blood genetic profiling test; Guardant Reveal, a liquid biopsy microscopic residual disease detection and recurrence monitoring test; and genetic rare disease testing services for chromosomal microarray, targeted exome sequencing, whole exome sequencing, and diagnostic genome sequencing. The compan...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 340450

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 9, 2026

Data Sources Report a data error